speb/financial-data huggingface dataset:
SYNGENE.NS cash_flow (annual, 2023-03-31) — Change In Payable: 2022000000.00
SYNGENE.NS cash_flow (annual, 2023-03-31) — Change In Receivables: 69000000.00
SYNGENE.NS cash_flow (annual, 2023-03-31) — Change In Working Capital: -182000000.00
SYNGENE.NS cash_flow (annual, 2023-03-31) — Changes In Cash: -1754000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Common Stock: 4014000000.00
SYNGENE.NS cash_flow (annual, 2023-03-31) — Common Stock Dividend Paid: -401000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Common Stock Equity: 36180000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Construction In Progress: 1923000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Cost Of Revenue: 8602000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Current Assets: 24253000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Current Capital Lease Obligation: 257000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Current Debt: 863000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Current Debt And Capital Lease Obligation: 1120000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Current Liabilities: 11882000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Current Provisions: 510000000.00
SYNGENE.NS cash_flow (annual, 2023-03-31) — Deferred Tax: 1292000000.00
SYNGENE.NS cash_flow (annual, 2023-03-31) — Depreciation: 3607000000.00
SYNGENE.NS cash_flow (annual, 2023-03-31) — Depreciation And Amortization: 3665000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Depreciation And Amortization In Income Statement: 3665000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Depreciation Income Statement: 3607000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Derivative Product Liabilities: 215000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Diluted Average Shares: 403620257.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Diluted EPS: 11.51
SYNGENE.NS income_statement (annual, 2023-03-31) — Diluted NI Availto Com Stockholders: 4644000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — EBIT: 6281000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — EBITDA: 9946000000.00
SYNGENE.NS cash_flow (annual, 2023-03-31) — Effect Of Exchange Rate Changes: 31000000.00
SYNGENE.NS cash_flow (annual, 2023-03-31) — End Cash Position: 895000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Financial Assets: 841000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 66000000.00
SYNGENE.NS cash_flow (annual, 2023-03-31) — Financing Cash Flow: -3425000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Finished Goods: 205000000.00
SYNGENE.NS cash_flow (annual, 2023-03-31) — Free Cash Flow: 3052000000.00
SYNGENE.NS cash_flow (annual, 2023-03-31) — Gain Loss On Investment Securities: -31000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — General And Administrative Expense: 1051000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Goodwill And Other Intangible Assets: 185000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Gross Accounts Receivable: 5376000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Gross PPE: 46123000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Gross Profit: 22200000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Hedging Assets Current: 460000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Interest Expense: 345000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Interest Expense Non Operating: 345000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Interest Income: 603000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Interest Income Non Operating: 603000000.00
SYNGENE.NS cash_flow (annual, 2023-03-31) — Interest Paid Cff: -345000000.00
SYNGENE.NS cash_flow (annual, 2023-03-31) — Interest Received Cfi: 540000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Inventory: 3328000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Invested Capital: 41933000000.00
SYNGENE.NS cash_flow (annual, 2023-03-31) — Investing Cash Flow: -6564000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Investment Properties: 481000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Investmentin Financial Assets: 2191000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Land And Improvements: 1070000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Long Term Capital Lease Obligation: 2142000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Long Term Debt: 4890000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Long Term Debt And Capital Lease Obligation: 7032000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Long Term Provisions: 437000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Machinery Furniture Equipment: 34101000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Minority Interests: 0.00
SYNGENE.NS cash_flow (annual, 2023-03-31) — Net Business Purchase And Sale: -182000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Net Debt: 4883000000.00
SYNGENE.NS cash_flow (annual, 2023-03-31) — Net Foreign Currency Exchange Gain Loss: 245000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Net Income: 4644000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Net Income Common Stockholders: 4644000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Net Income Continuous Operations: 4644000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Net Income From Continuing And Discontinued Operation: 4644000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Net Income From Continuing Operation Net Minority Interest: 4644000000.00
SYNGENE.NS cash_flow (annual, 2023-03-31) — Net Income From Continuing Operations: 4644000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Net Income Including Noncontrolling Interests: 4644000000.00
SYNGENE.NS cash_flow (annual, 2023-03-31) — Net Intangibles Purchase And Sale: -117000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Net Interest Income: 258000000.00
SYNGENE.NS cash_flow (annual, 2023-03-31) — Net Investment Purchase And Sale: -1739000000.00
SYNGENE.NS cash_flow (annual, 2023-03-31) — Net Issuance Payments Of Debt: -2581000000.00
SYNGENE.NS cash_flow (annual, 2023-03-31) — Net Long Term Debt Issuance: 0.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Net Non Operating Interest Income Expense: 258000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Net PPE: 27927000000.00
SYNGENE.NS cash_flow (annual, 2023-03-31) — Net PPE Purchase And Sale: -5066000000.00
SYNGENE.NS cash_flow (annual, 2023-03-31) — Net Short Term Debt Issuance: -2581000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Net Tangible Assets: 35995000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Revenue: 2564000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Assets: 696000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 437000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Non Current Prepaid Assets: 356000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Normalized EBITDA: 9925000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Normalized Income: 4627578000.00
SYNGENE.NS cash_flow (annual, 2023-03-31) — Operating Cash Flow: 8235000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Operating Income: 6182000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Operating Revenue: 30802000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Ordinary Shares Number: 399591554.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Other Current Assets: 104000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Other Current Liabilities: 6566000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Other Equity Interest: 654000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Other Intangible Assets: 185000000.00
SYNGENE.NS cash_flow (annual, 2023-03-31) — Other Non Cash Items: -259000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Other Non Current Assets: -1000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Other Non Current Liabilities: 2564000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Other Non Operating Income Expenses: 709000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Other Operating Expenses: 3727000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Other Payable: 1091000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Other Properties: 23834000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Other Receivables: 552000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Other Short Term Investments: 12666000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Other Special Charges: 75000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Otherunder Preferred Stock Dividend: 0.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Payables: 3818000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 510000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Prepaid Assets: 1059000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Pretax Income: 5936000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Properties: 0.00
SYNGENE.NS cash_flow (annual, 2023-03-31) — Provisionand Write Offof Assets: -17000000.00
SYNGENE.NS cash_flow (annual, 2023-03-31) — Purchase Of Business: -182000000.00
SYNGENE.NS cash_flow (annual, 2023-03-31) — Purchase Of Intangibles: -117000000.00
SYNGENE.NS cash_flow (annual, 2023-03-31) — Purchase Of Investment: -27667000000.00
SYNGENE.NS cash_flow (annual, 2023-03-31) — Purchase Of PPE: -5066000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Raw Materials: 2390000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Reconciled Cost Of Revenue: 8602000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Reconciled Depreciation: 3665000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Rent And Landing Fees: 44000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Rent Expense Supplemental: 44000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Restricted Cash: 25000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Retained Earnings: 29725000000.00
SYNGENE.NS cash_flow (annual, 2023-03-31) — Sale Of Investment: 25928000000.00
SYNGENE.NS cash_flow (annual, 2023-03-31) — Sale Of PPE: 0.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Selling And Marketing Expense: 185000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Selling General And Administration: 1236000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Share Issued: 401434500.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Special Income Charges: -85000000.00
SYNGENE.NS cash_flow (annual, 2023-03-31) — Stock Based Compensation: 236000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Stockholders Equity: 36180000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Tangible Book Value: 35995000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Tax Effect Of Unusual Items: 4578000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Tax Provision: 1292000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Tax Rate For Calcs: 0.22
SYNGENE.NS cash_flow (annual, 2023-03-31) — Taxes Refund Paid: -1368000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Total Assets: 58310000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Total Capitalization: 41070000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Total Debt: 8152000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Total Equity Gross Minority Interest: 36180000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Total Expenses: 24620000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Total Liabilities Net Minority Interest: 22130000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Total Non Current Assets: 34057000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Total Non Current Liabilities Net Minority Interest: 10248000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Total Tax Payable: 147000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Total Unusual Items: 21000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Total Unusual Items Excluding Goodwill: 21000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Treasury Shares Number: 1842946.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Treasury Stock: 47000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Work In Process: 733000000.00
SYNGENE.NS balance_sheet (annual, 2023-03-31) — Working Capital: 12371000000.00
SYNGENE.NS income_statement (annual, 2023-03-31) — Write Off: 10000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — +Operating Expense: 17922000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — +Total Revenue: 33695000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Accounts Payable: 2555000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Accounts Receivable: 4416000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Accumulated Depreciation: -20861000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Additional Paid In Capital: 2167000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Allowance For Doubtful Accounts Receivable: -132000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Amortization: 79000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Amortization Cash Flow: 79000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Available For Sale Securities: 283000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Basic Average Shares: 401379732.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Basic EPS: 12.71
SYNGENE.NS cash_flow (annual, 2024-03-31) — Beginning Cash Position: 895000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Buildings And Improvements: 11206000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Capital Expenditure: -5108000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Capital Lease Obligations: 4135000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Capital Stock: 4020000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Cash And Cash Equivalents: 856000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Cash Cash Equivalents And Short Term Investments: 10766000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Cash Dividends Paid: -503000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Cash Equivalents: 0.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Cash Financial: 856000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Change In Inventory: 893000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Change In Other Current Assets: 826000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Change In Payable: -1026000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Change In Receivables: 867000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Change In Working Capital: 1560000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Changes In Cash: -49000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Common Stock: 4020000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Common Stock Dividend Paid: -503000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Common Stock Equity: 42577000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Common Stock Issuance: 6000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Construction In Progress: 8444000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Cost Of Revenue: 9302000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Current Assets: 19590000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Current Capital Lease Obligation: 484000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Current Debt: 417000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Current Debt And Capital Lease Obligation: 901000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Current Liabilities: 11443000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Current Provisions: 727000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Deferred Tax: 950000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Depreciation: 4180000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Depreciation And Amortization: 4259000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Depreciation And Amortization In Income Statement: 4259000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Depreciation Income Statement: 4180000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Derivative Product Liabilities: 0.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Diluted Average Shares: 401971548.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Diluted EPS: 12.69
SYNGENE.NS income_statement (annual, 2024-03-31) — Diluted NI Availto Com Stockholders: 5100000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — EBIT: 6659000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — EBITDA: 10918000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Effect Of Exchange Rate Changes: 11000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — End Cash Position: 857000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Financial Assets: 1847000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 66000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Financing Cash Flow: -5514000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Finished Goods: 132000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Free Cash Flow: 5313000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Gain Loss On Investment Securities: -119000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — General And Administrative Expense: 1494000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Goodwill And Other Intangible Assets: 295000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Gross Accounts Receivable: 4548000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Gross PPE: 57115000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Gross Profit: 24393000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Hedging Assets Current: 694000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Interest Expense: 451000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Interest Expense Non Operating: 451000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Interest Income: 760000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Interest Income Non Operating: 760000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Interest Paid Cff: -288000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Interest Received Cfi: 815000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Inventory: 2385000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Invested Capital: 43994000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Investing Cash Flow: -4956000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Investment Properties: 411000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Investmentin Financial Assets: 349000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Issuance Of Capital Stock: 6000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Land And Improvements: 1504000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Long Term Capital Lease Obligation: 3651000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Long Term Debt: 1000000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Long Term Debt And Capital Lease Obligation: 4651000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Long Term Debt Payments: -3904000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Long Term Provisions: 407000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Machinery Furniture Equipment: 35961000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Minority Interests: 0.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Net Business Purchase And Sale: -5532000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Net Common Stock Issuance: 6000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Net Debt: 561000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Net Foreign Currency Exchange Gain Loss: -36000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Net Income: 5100000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Net Income Common Stockholders: 5100000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Net Income Continuous Operations: 5100000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Net Income From Continuing And Discontinued Operation: 5100000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Net Income From Continuing Operation Net Minority Interest: 5100000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Net Income From Continuing Operations: 5100000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Net Income Including Noncontrolling Interests: 5100000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Net Intangibles Purchase And Sale: -188000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Net Interest Income: 309000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Net Investment Purchase And Sale: 4648000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Net Issuance Payments Of Debt: -4362000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Net Long Term Debt Issuance: -3904000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Net Non Operating Interest Income Expense: 309000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Net Other Financing Charges: -1000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Net PPE: 36254000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Net PPE Purchase And Sale: -4699000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Net Short Term Debt Issuance: -458000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Net Tangible Assets: 42282000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Revenue: 2438000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Assets: 407000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 407000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Non Current Prepaid Assets: 443000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Normalized EBITDA: 10916000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Normalized Income: 5098356958.76
SYNGENE.NS cash_flow (annual, 2024-03-31) — Operating Cash Flow: 10421000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Operating Income: 6471000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Operating Revenue: 33695000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Ordinary Shares Number: 400771303.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Other Cash Adjustment Outside Changein Cash: 1000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Other Current Assets: 1122000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Other Current Liabilities: -1000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Other Equity Interest: 690000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Other Intangible Assets: 295000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Other Non Cash Items: -152000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Other Non Current Assets: -3000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Other Non Current Liabilities: 1000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Other Non Operating Income Expenses: 1000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Other Operating Expenses: 4148000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Other Payable: 1236000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Other Properties: 23783000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Other Receivables: 206000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Other Short Term Investments: 9910000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Other Special Charges: 25000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Otherunder Preferred Stock Dividend: 0.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Payables: 4267000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 727000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Prepaid Assets: 1122000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Pretax Income: 6208000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Properties: 0.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Provisionand Write Offof Assets: 99000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Purchase Of Business: -5532000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Purchase Of Intangibles: -188000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Purchase Of Investment: -40507000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Purchase Of PPE: -4920000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Raw Materials: 2014000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Reconciled Cost Of Revenue: 9302000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Reconciled Depreciation: 4259000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Rent And Landing Fees: 55000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Rent Expense Supplemental: 55000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Repayment Of Debt: -3904000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Restricted Cash: 1000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Restructuring And Mergern Acquisition: 111000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Retained Earnings: 34361000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Sale Of Investment: 45155000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Sale Of PPE: 221000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Selling And Marketing Expense: 203000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Selling General And Administration: 1697000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Share Issued: 402015000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Special Income Charges: -142000000.00
SYNGENE.NS cash_flow (annual, 2024-03-31) — Stock Based Compensation: 5000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Stockholders Equity: 42577000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Tangible Book Value: 42282000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Tax Effect Of Unusual Items: 356958.76
SYNGENE.NS income_statement (annual, 2024-03-31) — Tax Provision: 1108000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Tax Rate For Calcs: 0.18
SYNGENE.NS cash_flow (annual, 2024-03-31) — Taxes Refund Paid: -1251000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Total Assets: 61516000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Total Capitalization: 43577000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Total Debt: 5552000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Total Equity Gross Minority Interest: 42577000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Total Expenses: 27224000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Total Liabilities Net Minority Interest: 18939000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Total Non Current Assets: 41926000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Total Non Current Liabilities Net Minority Interest: 7496000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Total Tax Payable: 476000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Total Unusual Items: 2000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Total Unusual Items Excluding Goodwill: 2000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Treasury Shares Number: 1243697.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Treasury Stock: 53000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Work In Process: 239000000.00
SYNGENE.NS balance_sheet (annual, 2024-03-31) — Working Capital: 8147000000.00
SYNGENE.NS income_statement (annual, 2024-03-31) — Write Off: 6000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Accounts Payable: 2767000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Accounts Receivable: 4839000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Available For Sale Securities: 771000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Capital Lease Obligations: 4776000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Capital Stock: 4025000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Cash And Cash Equivalents: 2206000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Cash Cash Equivalents And Short Term Investments: 10415000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Common Stock: 4025000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Common Stock Equity: 43955000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Construction In Progress: 9036000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Current Assets: 18771000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Current Capital Lease Obligation: 523000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Current Debt: 587000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Current Debt And Capital Lease Obligation: 1110000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Current Liabilities: 9410000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Current Provisions: 818000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Derivative Product Liabilities: 20000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Financial Assets: 1554000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Goodwill And Other Intangible Assets: 298000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Gross PPE: 36972000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Hedging Assets Current: 670000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Inventory: 1705000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Invested Capital: 45547000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Investment Properties: 376000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Investmentin Financial Assets: 771000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Long Term Capital Lease Obligation: 4253000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt: 1005000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt And Capital Lease Obligation: 5258000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Long Term Provisions: 472000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Net PPE: 36972000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Net Tangible Assets: 43657000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Assets: 367000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Ordinary Shares Number: 401186345.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Other Current Assets: 1142000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Other Current Liabilities: 2858000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Other Equity Interest: 39930000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Other Intangible Assets: 298000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Assets: 143000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Liabilities: 2245000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Other Properties: 27936000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Other Short Term Investments: 8209000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Payables: 3304000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Share Issued: 402536981.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Stockholders Equity: 43955000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Tangible Book Value: 43657000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Total Assets: 61360000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Total Capitalization: 44960000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Total Debt: 6368000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Total Equity Gross Minority Interest: 43955000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Total Liabilities Net Minority Interest: 17405000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Assets: 42589000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Liabilities Net Minority Interest: 7995000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Total Tax Payable: 537000000.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Treasury Shares Number: 1350636.00
SYNGENE.NS balance_sheet (quarterly, 2024-09-30) — Working Capital: 9361000000.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — +Operating Expense: 5331000000.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — +Total Revenue: 9437000000.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — Basic Average Shares: 400917431.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — Basic EPS: 3.27
SYNGENE.NS income_statement (quarterly, 2024-12-31) — Cost Of Revenue: 2374000000.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — Depreciation And Amortization In Income Statement: 1087000000.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — Depreciation Income Statement: 1087000000.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — Diluted Average Shares: 402147239.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — Diluted EPS: 3.26
SYNGENE.NS income_statement (quarterly, 2024-12-31) — Diluted NI Availto Com Stockholders: 1311000000.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — EBIT: 1932000000.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — EBITDA: 3019000000.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — Gross Profit: 7063000000.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — Interest Expense: 124000000.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — Interest Expense Non Operating: 124000000.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — Net Income: 1311000000.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — Net Income Common Stockholders: 1311000000.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — Net Income Continuous Operations: 1311000000.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — Net Income From Continuing And Discontinued Operation: 1311000000.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: 1311000000.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — Net Income Including Noncontrolling Interests: 1311000000.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — Net Interest Income: -124000000.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — Net Non Operating Interest Income Expense: -124000000.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — Normalized EBITDA: 3019000000.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — Normalized Income: 1311000000.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — Operating Income: 1732000000.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — Operating Revenue: 9437000000.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — Other Non Operating Income Expenses: 183000000.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — Other Operating Expenses: 1749000000.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — Otherunder Preferred Stock Dividend: 0.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — Pretax Income: 1808000000.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — Reconciled Cost Of Revenue: 2374000000.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — Reconciled Depreciation: 1087000000.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — Special Income Charges: 0.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — Tax Effect Of Unusual Items: 0.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — Tax Provision: 497000000.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — Tax Rate For Calcs: 0.27
SYNGENE.NS income_statement (quarterly, 2024-12-31) — Total Expenses: 7705000000.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — Total Unusual Items: 0.00
SYNGENE.NS income_statement (quarterly, 2024-12-31) — Total Unusual Items Excluding Goodwill: 0.00
SYNGENE.NS income_statement (annual, 2025-03-31) — +Operating Expense: 19569000000.00
SYNGENE.NS income_statement (quarterly, 2025-03-31) — +Operating Expense: 5409000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — +Total Revenue: 35128000000.00
SYNGENE.NS income_statement (quarterly, 2025-03-31) — +Total Revenue: 10180000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Accounts Payable: 3520000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 3520000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Accounts Receivable: 5268000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 5268000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Accumulated Depreciation: -24028000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -24028000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Additional Paid In Capital: 2437000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 2437000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -181000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -181000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Amortization: 89000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Amortization Cash Flow: 89000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Available For Sale Securities: 314000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Available For Sale Securities: 314000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Basic Average Shares: 401925774.00
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Basic Average Shares: 401973684.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Basic EPS: 12.35
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Basic EPS: 4.56
SYNGENE.NS cash_flow (annual, 2025-03-31) — Beginning Cash Position: 857000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Buildings And Improvements: 11606000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Buildings And Improvements: 11606000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Capital Expenditure: -7701000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Capital Lease Obligations: 4583000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 4583000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Capital Stock: 4025000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Capital Stock: 4025000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Cash And Cash Equivalents: 3669000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 3669000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 13973000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 13973000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Cash Dividends Paid: -503000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Cash Equivalents: 854000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Cash Equivalents: 854000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Cash Financial: 2815000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Cash Financial: 2815000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Change In Inventory: 743000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Change In Other Current Assets: -126000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Change In Payable: 1843000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Change In Receivables: -939000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Change In Working Capital: 1521000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Changes In Cash: 2811000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Common Stock: 4025000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Common Stock: 4025000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Common Stock Dividend Paid: -503000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Common Stock Equity: 47269000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 47269000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Common Stock Issuance: 5000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Construction In Progress: 12888000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Construction In Progress: 12888000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Cost Of Revenue: 9425000000.00
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 2350000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Current Assets: 22873000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Current Assets: 22873000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Current Capital Lease Obligation: 495000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 495000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Current Debt: 1196000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Current Debt: 1196000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Current Debt And Capital Lease Obligation: 1691000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 1691000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Current Liabilities: 13964000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 13964000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Current Provisions: 713000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Current Provisions: 713000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Deferred Tax: 1589000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Depreciation: 4237000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Depreciation And Amortization: 4326000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Depreciation And Amortization In Income Statement: 4326000000.00
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 1061000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Depreciation Income Statement: 4237000000.00
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Depreciation Income Statement: 1061000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Derivative Product Liabilities: 18000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Derivative Product Liabilities: 18000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Diluted Average Shares: 402317990.00
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 401973684.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Diluted EPS: 12.34
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Diluted EPS: 4.56
SYNGENE.NS income_statement (annual, 2025-03-31) — Diluted NI Availto Com Stockholders: 4962000000.00
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 1833000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — EBIT: 7091000000.00
SYNGENE.NS income_statement (quarterly, 2025-03-31) — EBIT: 2564000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — EBITDA: 11417000000.00
SYNGENE.NS income_statement (quarterly, 2025-03-31) — EBITDA: 3625000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Effect Of Exchange Rate Changes: 3000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — End Cash Position: 3671000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Financial Assets: 1706000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Financial Assets: 1706000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 66000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 66000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Financing Cash Flow: -1418000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Finished Goods: 58000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Finished Goods: 58000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Free Cash Flow: 3975000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Gain Loss On Investment Securities: -133000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — General And Administrative Expense: 1696000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Goodwill And Other Intangible Assets: 303000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 303000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Gross Accounts Receivable: 5449000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Gross Accounts Receivable: 5449000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Gross PPE: 64336000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Gross PPE: 64336000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Gross Profit: 25703000000.00
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Gross Profit: 7830000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Hedging Assets Current: 532000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Hedging Assets Current: 532000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Interest Expense: 492000000.00
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Interest Expense: 159000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Interest Expense Non Operating: 492000000.00
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 159000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Interest Income: 559000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Interest Income Non Operating: 559000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Interest Paid Cff: -138000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Interest Received Cfi: 503000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Inventory: 1555000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Inventory: 1555000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Invested Capital: 48465000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Invested Capital: 48465000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Investing Cash Flow: -7447000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Investment Properties: 343000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Investment Properties: 343000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Investmentin Financial Assets: 380000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 380000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Issuance Of Capital Stock: 5000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Land And Improvements: 1819000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Land And Improvements: 1819000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Long Term Capital Lease Obligation: 4088000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 4088000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Long Term Debt: 0.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 0.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 4088000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 4088000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Long Term Debt Payments: -417000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Long Term Provisions: 433000000.00